INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA

Group 1 - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. concerning potential securities fraud or unlawful business practices by the company and its officers [2][4] - Iovance reported a significant decline in quarterly total product revenue for Q1 2025, amounting to $49.3 million, down from $73.7 million in the previous quarter [4] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [4] Group 2 - Following the release of the financial results and guidance revision, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [4] - Investors have until July 14, 2025, to request to be appointed as Lead Plaintiff in the class action if they purchased Iovance securities during the Class Period [2]